Olswang has advised UK-headquartered leading provider of patent translations RWS Holdings on the $70 million acquisition of Corporate Translations Inc (CTi), a US-based leading life sciences translation and linguistic validation provider.

RWS is one of the leading players in the provision of intellectual property support services and high-level technical, medical, commercial, legal and financial translation services. The acquisition, which has fully completed, is in line with RWS' strategy of complementing organic growth with the deployment of the Group's cash resources for selective acquisitions which have demonstrable growth prospects in attractive sectors and/or geographies, offer excellent margins and can enhance shareholder value.

Olswang has acted for RWS on various matters since 1990 and advised it on the acquisition finance and UK aspects of this deal.

RWS Chairman Andrew Brode commented: “We are delighted to have acquired CTi, which furthers our reach in the life sciences sector. It was a pleasure to be advised by Olswang on various aspects of the transaction, and Nick, Charles and their team’s expertise was invaluable as we progressed through the deal.”

Olswang Corporate Partner Nick Crosbie said: “We were pleased to act for long-standing client RWS on their latest acquisition. CTi brings RWS skill and expertise in the life sciences sector, and we look forward to seeing how they will grow their footprint in the European market in the years to come.”

Olswang’s Corporate team was led by Partner Nick Crosbie and Associate Julian Ciecierski-Burns, and the Finance team was led by Partner and Head of Finance Charles Kerrigan and Legal Director Anne Chitan together with Associates Gurminder Muker and Vassilya Konstantinovitch.